OC
ADPT icon

Oppenheimer & Co’s Adaptive Biotechnologies ADPT Stock Holding History

Oppenheimer & Co’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,556
Closed -$265K – 1255
2020
Q1 		$265K Sell
9,556
-912
-9% -$25.4K 0.01% 941
2019
Q4 		$313K Buy
+10,468
New +$301K 0.01% 1008

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

Oppenheimer & Co's ADPT Position: Q2 2020 in Review

Oppenheimer & Co sold out of Adaptive Biotechnologies (ADPT) in Q2 2020, closing a stake of 9,556 shares — an estimated $265K sold.

Oppenheimer & Co first reported a position in ADPT in Q4 2019 and held it in 2 quarters. The position peaked at $313K in Q4 2019. 196 funds tracked by Wall St. Rank hold ADPT as of Q2 2020.

  • Oppenheimer & Co reported no remaining Adaptive Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • Oppenheimer & Co sold 9,556 Adaptive Biotechnologies shares in Q2 2020, an estimated $265K.
  • Oppenheimer & Co first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 2 quarters.
  • Oppenheimer & Co's Adaptive Biotechnologies position peaked at $313K in Q4 2019.
  • 196 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2020.

Based on Oppenheimer & Co's 13F filing for Q2 2020, filed 11 Aug 2020.